All In Biotech

Drug Trial Radar · NCT05954312

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

A Phase 1, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of VVD-130037, a Kelch-like ECH Associated Protein 1 (KEAP1) Activator, in Participants With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 290 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

290

Planned (sponsor's estimate)

Start

Jul 28, 2023

Primary completion

Aug 31, 2030

Study completion Feb 28, 2031

Sponsor

Lead sponsor
Vividion Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jul 20, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A FIH dose escalation and dose expansion study to evaluate VVD-130037 in participants with advanced solid tumors as a single agent, and in combination with docetaxel, paclitaxel, or pembrolizumab.

Conditions

  • Advanced Solid Tumors

Interventions

  • VVD-130037Drug

    Oral tablets

  • DocetaxelDrug

    IV infusion

  • PaclitaxelDrug

    IV infusion

  • PembrolizumabDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 (Dose Escalation): Incidence and Severity of Dose-limiting Toxicities (DLTs) During DLT Observation PeriodTime frame: Part 1: Single Agent and Docetaxel/Pembrolizumab Combination Therapy: From Day 1 to Day 21 of Cycle 1 [cycle length=21 days] and Part 1: Paclitaxel Combination Therapy: From Day 1 to Day 28 of Cycle 1 [cycle length=28 days]
  2. Part 2 (Dose Expansion): Number of Participants With AEs, Serious Adverse Events (SAEs), and Clinical Laboratory AbnormalitiesTime frame: Up to approximately 4 years

Locations

26 sites in 3 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Jacksonville

    Jacksonville, Florida · Recruiting

  • Florida Cancer Specialists

    Sarasota, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Mayo Clinic Rochester

    Rochester, Minnesota · Recruiting

  • Sarah Cannon Research Institute

    Nashville, Tennessee · Recruiting

  • MDACC

    Houston, Texas · Recruiting

  • NEXT Dallas

    Irving, Texas · Recruiting

  • NEXT Virginia

    Fairfax, Virginia · Recruiting

  • National Cancer Center

    Goyang, South Korea · Recruiting

  • The Catholic University of Korea, St. Vincent's Hospital

    Goyang, South Korea · Recruiting

  • Gachon University Gil Medical Center

    Incheon, South Korea · Recruiting

  • Seoul National University; Bundang Hospital

    Seongnam, South Korea · Recruiting

  • Asan Medical Center

    Seoul, South Korea · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

  • Severance Hospital; Yonsei University Health System

    Seoul, South Korea · Recruiting

  • The Catholic University of Korea, St. Vincent's Hospital

    Suwon, South Korea · Recruiting

  • Hospital Vall d'Hebron

    Barcelona, Spain · Recruiting

  • START Barcelona Hospital HM Nou Delfos

    Barcelona, Spain · Recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Spain · Recruiting

  • Hospital Universitario Ramon y Cajal

    Madrid, Spain · Recruiting

  • NEXT Madrid

    Madrid, Spain · Recruiting

  • START Madrid CIOCC

    Madrid, Spain · Recruiting

  • Start Madrid-FJD, Hospital Fundacion Jimenez Diaz

    Madrid, Spain · Recruiting

  • Clinica Universitaria de Navarra

    Pamplona, Spain · Recruiting

  • Hospital Clinico Universitario de Valencia

    Valencia, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.